12:00 AM
 | 
Feb 27, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Zelboraf vemurafenib regulatory update

The European Commission approved an MAA from Roche for Zelboraf vemurafenib to treat unresectable or metastatic melanoma in patients with BRAF V600 mutations. Roche already has CE Mark approval in...

Read the full 140 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >